




FIG. 1a




FIG. 1b








FIG. 1c

**FIG. 1d****FIG. 1e**

**FIG. 1f**

**Toxicity as Assessed
by Median Weight Change**

**FIG. 1g**

24 h Biodistribution studies: Saponins 6 and




FIG. 2a

24 h Imaging studies: Site of Injection





FIG. 2b

24 h Imaging studies: Dissected lymph nodes**FIG. 2c**











FIG. 3a


**FIG. 3b****FIG. 3c**


**FIG. 3d****FIG. 3e**

**FIG. 4a****FIG. 4b**

**FIG. 4c**



**Toxicity as Assessed by
Median Weight Change**


**FIG. 4d**






Saponin	R ¹	R ²	Triterpene
16 (SQS 1-0-5-18)	-CHO	-OH	Quillaic acid
19 (SQS 1-11-5-18)	-CH ₂ OH	-OH	Caulophyllogenin
20 (SQS 1-8-5-18)	-Me	-OH	Echinocystic acid
21 (SQS 1-9-5-18)	-CHO	-H	Gypsogenin
22 (SQS 1-10-5-18)	-CH ₂ OH	-H	Hederagenin
18 (SQS 1-7-5-18)	-Me	-H	Cleanolic acid

FIG. 5a

**FIG. 5b****FIG. 5c**

**FIG. 5d**

**FIG. 5e****FIG. 5f**

**FIG. 5g**

24 h Biodistribution studies: Saponins 16 and 18




FIG. 6






FIG. 7a

**FIG. 7b**

Extended biodistribution studies:
Saponin [^{131}I]-6 in presence of OVA




FIG. 8a

Extended biodistribution studies:
Saponin [^{131}I]-8 in presence of OVA




FIG. 8b

Extended biodistribution studies:
Saponin [^{131}I]-6 in absence of OVA




FIG. 9a

**Extended biodistribution studies:
Saponin [^{131}I]-8 in absence of OVA**




FIG. 9b




FIG. 9d




FIG. 9c

Extended biodistribution studies:
 $[^{131}\text{I}]\text{-OVA}$ in presence of 6






FIG. 10a

**FIG. 10b**

24 h Imaging studies: Site of injection
Fluorescein imaging



Mouse 1
10 μ g 3 (SQS-0-0.5-12)
+ 20 μ g OVA-A647

Mouse 2
10 μ g 2 (SQS-0-0.5-11)
+ 20 μ g OVA-A647

FIG. 11




FIG. 12




FIG. 13




FIG. 14










FIG. 15

**FIG. 16a****FIG. 16b**

**FIG. 16c****FIG. 16d**

**FIG. 16e**

**Toxicity as Assessed by
Median Weight Change**

**FIG. 16f**